Clinical Trial Detail

NCT ID NCT03368859
Title A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine/Oxaliplatin and Bevacizumab
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors AbbVie
Indications

colon adenocarcinoma

rectum adenocarcinoma

Therapies

ABT-165 + Fluorouracil + Irinotecan + Leucovorin

Bevacizumab + Fluorouracil + Irinotecan + Leucovorin

Age Groups: adult senior

No variant requirements are available.